Replies to post #802 on Sophiris Bio Inc fka SPHS

[ash111]

http://stocktwits.com/symbol/SPHS. "No shares to short from every broker".

Treatment has “blockbuster” potential – meaning annual sales of more than $1 billion". http://www.pharmalive.com/sophiriss-prostate-drug-meets-main-goal-in-late-stage-study/

market cap is way undervalued for positive P3,Way below it's competitor($130M) and way below other bio(s).the competitor trading at $130m cap on negative cash flow while SPHS already funded to both P3 and P2 ( q1 2016). The balance sheet solid as well.only 16m O/S,most of shares have been bought at these prices.this stock was trading Over $20.
just do math.SPHS just Defeated it's competitor and actually won twice.

SPHS already Funded to P2 Localized prostate cancer(huge mrkt,Q1 2016 DATA!), and P3 BPH(huge mrkt) results( REPORTED POSITIVE DATA)
Strong Mgmt, Good IP and patent longevity. Drug not difficult or overly expensive to produce. "We expect that our cash, cash equivalents and securities available-for-sale as of June 30, 2015 will be sufficient to fund our operations through the end of April 2016"

no more sub-dollar,no more nasdaq warning, Institutional & Mutual Fund will be able to buy shares here now.